Damora Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
DMRA$24.15+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(in thousands, except share amounts)
| Mezzanine Equity · Stockholders' Equity | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Three Months Ended · Preferred Stock · Common Stock · AdditionalPaid-In · Accumulated · Accumulated OtherComprehensive · TotalStockholders’ | |||||||||||||||
| March 31, 2025 · Shares · Amount · Shares · Amount · Capital · Deficit · Income (Loss) · Equity | |||||||||||||||
| Balance at December 31, 2024 | 161 | $1,360 | 1,316,989 | $— | $291,898 | $(277,524) | $97 | $15,831 | |||||||
| Stock-based compensation expense | — | — | — | — | 179 | — | — | 179 | |||||||
| Issuance of common stock in connection with vesting of restricted stock units | — | — | 5,370 | — | 29 | — | — | 29 | |||||||
| Other comprehensive income, net | — | — | — | — | — | — | 203 | 203 | |||||||
| Net loss | — | — | — | — | — | (2,533) | — | (2,533) | |||||||
| Balance at March 31, 2025 | 161 | $1,360 | 1,322,359 | $— | $292,106 | $(280,057) | $300 | $13,709 | |||||||
| Mezzanine Equity · Stockholders' Equity | |||||||||||||||
| Three Months Ended | Preferred Stock | Common Stock | AdditionalPaid-In | Accumulated | Accumulated OtherComprehensive | TotalStockholders’ | |||||||||
| March 31, 2024 | Shares | Amount | Shares | Amount | Capital | Deficit | Income (Loss) | Equity | |||||||
| Balance at December 31, 2023 | — | $— | 1,084,509 | $— | $288,036 | $(256,085) | $380 | $32,331 | |||||||
| Stock-based compensation expense | — | — | — | — | 1,359 | — | — | 1,359 | |||||||
| Other comprehensive loss, net | — | — | — | — | — | — | (54) | (54) | |||||||
| Net loss | — | — | — | — | — | (5,477) | — | (5,477) | |||||||
| Balance at March 31, 2024 | — | $— | 1,084,509 | $— | $289,395 | $(261,562) | $326 | $28,159 | |||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.